Heimans J J, Vermorken J B, Wolbers J G, Eeltink C M, Meijer O W, Taphoorn M J, Beijnen J H
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
Ann Oncol. 1994 Dec;5(10):951-3. doi: 10.1093/oxfordjournals.annonc.a058736.
Paclitaxel (Taxol) is a novel chemotherapeutic agent, active against a variety of tumors. It is not known whether the drug penetrates brain tumor tissue.
Three patients with a recurrent glioma received paclitaxel (175 mg/m2) in a 3-hour i.v. infusion prior to surgery. Paclitaxel concentrations were measured in the tumor tissue, cerebrospinal fluid, cyst fluid, plasma and, in one patient, normal brain tissue.
Tumor tissue concentrations were in the therapeutic range in all three patients. Brain tissue concentration, however, was below the detection limit of the trial.
These findings suggest that paclitaxel may have a place in brain tumor therapy. The low concentration in normal brain tissue, as observed in one patient, may suggest, however, that the drug does not cross the intact bloodbrain barrier.
紫杉醇（泰素）是一种新型化疗药物，对多种肿瘤具有活性。目前尚不清楚该药物是否能穿透脑肿瘤组织。
3例复发性胶质瘤患者在手术前接受3小时静脉输注紫杉醇（175mg/m²）。在肿瘤组织、脑脊液、囊液、血浆以及1例患者的正常脑组织中测量紫杉醇浓度。
所有3例患者的肿瘤组织浓度均在治疗范围内。然而，脑组织浓度低于试验检测限。
这些发现表明紫杉醇可能在脑肿瘤治疗中占有一席之地。不过，在1例患者中观察到的正常脑组织中低浓度，可能提示该药物不能穿过完整的血脑屏障。
